Marsh & McLennan (MRSH): What to Expect from Q1 2026 Earnings
Key Takeaways
- Analysts expect Q1 2026 adjusted EPS of $3.23, up 5.5% from $3.06 in Q1 2025.
- Consensus revenue forecast stands at $7.4 billion, reflecting 4.6% year-over-year growth.
- Marsh & McLennan has beaten EPS estimates in the last four quarters, with surprises averaging over 4%.
- Full-year 2026 EPS consensus is $10.36, implying 6.3% growth from 2025's $9.75.
- Investors will watch underlying revenue growth and margin trends amid softening insurance pricing.
- Earnings release scheduled for April 16, 2026, before market open, followed by conference call at 8:30 a.m. EDT.
Earnings Context and Why It Matters
Marsh & McLennan Companies, Inc. (MRSH), a leading global professional services firm, operates through its Risk and Insurance Services (RIS) and Consulting segments, providing risk management, insurance broking, and health/wealth consulting. This Q1 2026 earnings report feels particularly significant to me as it represents the first under the new "Marsh" branding following the January 2026 ticker change from MMC. In a landscape marked by moderating reinsurance pricing and economic uncertainty, I'm looking for confirmation that the company can sustain its underlying revenue growth—around 4% in 2025—and continue expanding margins. The recent Q4 2025 results, with 9% adjusted EPS growth to $2.12 and a 7.6% beat on estimates, highlighted that resilience. A strong showing here could help justify MRSH's premium valuation at a P/E of 20.5 and its attractive 2.1% dividend yield, while any miss could weigh on shares given broader market volatility.
Earnings Expectations
Wall Street's consensus calls for adjusted EPS of $3.23 in the first quarter ended March 31, 2026, marking a 5.5% rise from $3.06 a year earlier, according to 21 analysts. Revenue is projected at $7.4 billion, up about 4.6% year-over-year based on estimates from 12 firms. This outlook fits the historical pattern where RIS—encompassing Marsh Risk and Guy Carpenter—and Consulting, including Mercer and Oliver Wyman, have delivered balanced contributions.
From what I see, key metrics to track include underlying revenue growth, which should mirror 2025's 4%; adjusted operating margin, which rose 30 basis points to around 24% last year; and trends in fiduciary investment income. MRSH has consistently outperformed EPS forecasts over the past four quarters: Q4 2025 (+7.4% surprise), Q3 (+4.1%), Q2 (+2.1%), and Q1 (+2.1%). Stock reactions to these beats have been modestly positive, with average gains on the smaller side. Management hasn't issued formal 2026 guidance yet, but they've signaled ongoing momentum even with headwinds from lower interest rates and softening insurance pricing.
Market Reaction and Investor Sentiment
Sentiment heading into these Q1 results strikes me as cautiously optimistic, supported by four consecutive EPS beats and 2025's full-year adjusted EPS growth of 9% to $9.75. That said, shares are down about 9% year-to-date amid market pressures and worries over easing insurance rates, currently trading at $172.58 with an $83.6 billion market cap. Risks on my radar include elevated operating costs and fiduciary income swings from declining rates. Post-earnings moves have averaged 2-3% historically, tending toward upside on beats, and analysts remain bullish with full-year EPS growth pegged at 6.3%.
Tickeron’s AI Screener: A Tool I Rely On
In my analysis, I often turn to Tickeron’s AI Screener, an AI-powered tool for discovering stocks and ETFs by filtering on technical patterns, fundamentals, trends, volatility, and AI signals. It lets me scan thousands of names using customizable criteria like industry, market cap, technical indicators, price patterns, and performance metrics—far more efficiently than manual methods. This has helped me spot trade ideas, trending stocks, breakouts, and opportunities across portfolios. I also checked this using Tickeron’s AI Screener to see how MRSH stacks up against industry peers.
Forward Outlook and Key Factors to Watch
Once Q1 numbers are out, I'll be paying close attention to management's take on the 2026 path. They should reaffirm underlying revenue growth near 4%, akin to 2025, fueled by RIS demand for risk advisory in areas like cyber and climate risks, alongside Consulting's health and wealth offerings.
One thing that stands out is margin expansion, with adjusted operating margins reaching 24% last year via efficiency improvements. Updates on share repurchases—$2 billion in 2025—and the $3.60 annual dividend, paid quarterly at $0.90 per share, will matter too.
I'm watching broader factors like reinsurance pricing normalization and interest rate effects on fiduciary investment income, which is interest earned on client funds. Future catalysts include Q2 results in July, M&A in transactional risk (a record in 2025), and Mercer's private markets funds. Maintaining cost discipline while retaining talent will be crucial in this competitive brokerage space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MRSH's Stochastic Oscillator is sitting in oversold zone for 8 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MRSH advanced for three days, in of 364 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 290 cases where MRSH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on April 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRSH as a result. In of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for MRSH turned negative on April 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .
MRSH moved below its 50-day moving average on April 23, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRSH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MRSH broke above its upper Bollinger Band on April 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRSH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. MRSH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.491) is normal, around the industry mean (5.987). P/E Ratio (20.754) is within average values for comparable stocks, (27.512). Projected Growth (PEG Ratio) (1.620) is also within normal values, averaging (1.561). Dividend Yield (0.022) settles around the average of (0.019) among similar stocks. P/S Ratio (2.967) is also within normal values, averaging (3.054).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
Advertisement